-
1
-
-
58149398623
-
Translation of the Philadelphia chromosome into therapy for CML
-
Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008; 112(13):4808-4817.
-
(2008)
Blood
, vol.112
, Issue.13
, pp. 4808-4817
-
-
Druker, B.J.1
-
2
-
-
79251506692
-
Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia
-
O'Hare T, Deininger MW, Eide CA, Clackson T and Druker BJ. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(2):212-221.
-
(2011)
Clinical cancer research: an official journal of the American Association for Cancer Research
, vol.17
, Issue.2
, pp. 212-221
-
-
O'Hare, T.1
Deininger, M.W.2
Eide, C.A.3
Clackson, T.4
Druker, B.J.5
-
3
-
-
61849163272
-
Molecular biology of bcr-abl1-positive chronic myeloid leukemia
-
Quintas-Cardama A and Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009; 113(8):1619-1630.
-
(2009)
Blood
, vol.113
, Issue.8
, pp. 1619-1630
-
-
Quintas-Cardama, A.1
Cortes, J.2
-
4
-
-
0036769168
-
Imatinib: a selective tyrosine kinase inhibitor
-
Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, Meyer T and Zimmermann J. Imatinib: a selective tyrosine kinase inhibitor. European journal of cancer. 2002; 38(Suppl 5):S19-27.
-
(2002)
European journal of cancer
, vol.38
, pp. S19-27
-
-
Manley, P.W.1
Cowan-Jacob, S.W.2
Buchdunger, E.3
Fabbro, D.4
Fendrich, G.5
Furet, P.6
Meyer, T.7
Zimmermann, J.8
-
5
-
-
0034665713
-
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
-
Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B and Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000; 289(5486):1938-1942.
-
(2000)
Science
, vol.289
, Issue.5486
, pp. 1938-1942
-
-
Schindler, T.1
Bornmann, W.2
Pellicena, P.3
Miller, W.T.4
Clarkson, B.5
Kuriyan, J.6
-
6
-
-
65249185560
-
Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia
-
Quintas-Cardama A, Kantarjian HM and Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009; 16(2):122-131.
-
(2009)
Cancer Control
, vol.16
, Issue.2
, pp. 122-131
-
-
Quintas-Cardama, A.1
Kantarjian, H.M.2
Cortes, J.E.3
-
7
-
-
49149111543
-
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis
-
de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM and Marin D. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008; 26(20):3358-3363.
-
(2008)
J Clin Oncol
, vol.26
, Issue.20
, pp. 3358-3363
-
-
de Lavallade, H.1
Apperley, J.F.2
Khorashad, J.S.3
Milojkovic, D.4
Reid, A.G.5
Bua, M.6
Szydlo, R.7
Olavarria, E.8
Kaeda, J.9
Goldman, J.M.10
Marin, D.11
-
8
-
-
67349233062
-
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
-
Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA and Investigators I. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009; 23(6):1054-1061.
-
(2009)
Leukemia
, vol.23
, Issue.6
, pp. 1054-1061
-
-
Hochhaus, A.1
O'Brien, S.G.2
Guilhot, F.3
Druker, B.J.4
Branford, S.5
Foroni, L.6
Goldman, J.M.7
Muller, M.C.8
Radich, J.P.9
Rudoltz, M.10
Mone, M.11
Gathmann, I.12
Hughes, T.P.13
Larson, R.A.14
Investigators, I.15
-
9
-
-
80052383499
-
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
-
Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA and Hughes TP. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011; 12(9):841-851.
-
(2011)
Lancet Oncol
, vol.12
, Issue.9
, pp. 841-851
-
-
Kantarjian, H.M.1
Hochhaus, A.2
Saglio, G.3
De Souza, C.4
Flinn, I.W.5
Stenke, L.6
Goh, Y.T.7
Rosti, G.8
Nakamae, H.9
Gallagher, N.J.10
Hoenekopp, A.11
Blakesley, R.E.12
Larson, R.A.13
Hughes, T.P.14
-
10
-
-
33750937577
-
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice
-
Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY and Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(45):16870-16875.
-
(2006)
Proceedings of the National Academy of Sciences of the United States of America
, vol.103
, Issue.45
, pp. 16870-16875
-
-
Hu, Y.1
Swerdlow, S.2
Duffy, T.M.3
Weinmann, R.4
Lee, F.Y.5
Li, S.6
-
11
-
-
0042346377
-
Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis
-
Danen-Van O, Orschot AA, Zhang YH, Leliveld SR, Rohn JL, Seelen MC, Bolk MW, Van Zon A, Erkeland SJ, Abrahams JP, Mumberg D and Noteborn MH. Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. The Journal of biological chemistry. 2003; 278(30):27729-27736.
-
(2003)
The Journal of biological chemistry
, vol.278
, Issue.30
, pp. 27729-27736
-
-
Danen-Van, O.1
Orschot, A.A.2
Zhang, Y.H.3
Leliveld, S.R.4
Rohn, J.L.5
Seelen, M.C.6
Bolk, M.W.7
Van Zon, A.8
Erkeland, S.J.9
Abrahams, J.P.10
Mumberg, D.11
Noteborn, M.H.12
-
12
-
-
84931839372
-
Apoptins: selective anticancer agents
-
(In press)
-
Rollano Peñaloza OM, Lewandowska M, Stetefeld J, Ossysek K, Madej M, Bereta J, Sobczak M, Shojaei S, Ghavami S and Los MJ. Apoptins: selective anticancer agents. Trends in molecular medicine. 2014; 20 (In press), doi: 10.1016/j.molmed.2014.07.003.
-
(2014)
Trends in molecular medicine
, vol.20
-
-
Rollano Peñaloza, O.M.1
Lewandowska, M.2
Stetefeld, J.3
Ossysek, K.4
Madej, M.5
Bereta, J.6
Sobczak, M.7
Shojaei, S.8
Ghavami, S.9
Los, M.J.10
-
13
-
-
32544433725
-
Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent
-
Burek M, Maddika S, Burek CJ, Daniel PT, Schulze-Osthoff K and Los M. Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent. Oncogene. 2006; 25(15):2213-2222.
-
(2006)
Oncogene
, vol.25
, Issue.15
, pp. 2213-2222
-
-
Burek, M.1
Maddika, S.2
Burek, C.J.3
Daniel, P.T.4
Schulze-Osthoff, K.5
Los, M.6
-
14
-
-
67651122925
-
Apoptin, a tumor-selective killer
-
Los M, Panigrahi S, Rashedi I, Mandal S, Stetefeld J, Essmann F and Schulze-Osthoff K. Apoptin, a tumor-selective killer. Biochim Biophys Acta. 2009; 1793(8):1335-1342.
-
(2009)
Biochim Biophys Acta
, vol.1793
, Issue.8
, pp. 1335-1342
-
-
Los, M.1
Panigrahi, S.2
Rashedi, I.3
Mandal, S.4
Stetefeld, J.5
Essmann, F.6
Schulze-Osthoff, K.7
-
15
-
-
27644584179
-
Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway
-
Maddika S, Booy EP, Johar D, Gibson SB, Ghavami S and Los M. Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. Journal of cell science. 2005; 118(Pt 19):4485-4493.
-
(2005)
Journal of cell science
, vol.118
, pp. 4485-4493
-
-
Maddika, S.1
Booy, E.P.2
Johar, D.3
Gibson, S.B.4
Ghavami, S.5
Los, M.6
-
16
-
-
32544447245
-
Cancer-selective therapy of the future: apoptin and its mechanism of action
-
Maddika S, Mendoza FJ, Hauff K, Zamzow CR, Paranjothy T and Los M. Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer biology & therapy. 2006; 5(1):10-19.
-
(2006)
Cancer biology & therapy
, vol.5
, Issue.1
, pp. 10-19
-
-
Maddika, S.1
Mendoza, F.J.2
Hauff, K.3
Zamzow, C.R.4
Paranjothy, T.5
Los, M.6
-
17
-
-
43449130891
-
Interaction with PI3-kinase contributes to the cytotoxic activity of apoptin
-
Maddika S, Wiechec E, Ande SR, Poon IK, Fischer U, Wesselborg S, Jans DA, Schulze-Osthoff K and Los M. Interaction with PI3-kinase contributes to the cytotoxic activity of apoptin. Oncogene. 2008; 27(21):3060-3065.
-
(2008)
Oncogene
, vol.27
, Issue.21
, pp. 3060-3065
-
-
Maddika, S.1
Wiechec, E.2
Ande, S.R.3
Poon, I.K.4
Fischer, U.5
Wesselborg, S.6
Jans, D.A.7
Schulze-Osthoff, K.8
Los, M.9
-
18
-
-
4043178615
-
The viral protein Apoptin associates with the anaphase-promoting complex to induce G2/M arrest and apoptosis in the absence of p53
-
Teodoro JG, Heilman DW, Parker AE and Green MR. The viral protein Apoptin associates with the anaphase-promoting complex to induce G2/M arrest and apoptosis in the absence of p53. Genes & development. 2004; 18(16):1952-1957.
-
(2004)
Genes & development
, vol.18
, Issue.16
, pp. 1952-1957
-
-
Teodoro, J.G.1
Heilman, D.W.2
Parker, A.E.3
Green, M.R.4
-
19
-
-
84855570062
-
Modeling of molecular interaction between apoptin, BCR-Abl and CrkL-an alternative approach to conventional rational drug design
-
Panigrahi S, Stetefeld J, Jangamreddy JR, Mandal S, Mandal SK and Los M. Modeling of molecular interaction between apoptin, BCR-Abl and CrkL-an alternative approach to conventional rational drug design. PLoS One. 2012; 7(1):e28395.
-
(2012)
PLoS One
, vol.7
, Issue.1
, pp. e28395
-
-
Panigrahi, S.1
Stetefeld, J.2
Jangamreddy, J.R.3
Mandal, S.4
Mandal, S.K.5
Los, M.6
-
20
-
-
0028410481
-
Critical residues in an SH3 domain from Sem-5 suggest a mechanism for proline-rich peptide recognition
-
Lim WA and Richards FM. Critical residues in an SH3 domain from Sem-5 suggest a mechanism for proline-rich peptide recognition. Nat Struct Biol. 1994; 1(4):221-225.
-
(1994)
Nat Struct Biol
, vol.1
, Issue.4
, pp. 221-225
-
-
Lim, W.A.1
Richards, F.M.2
-
21
-
-
0035885925
-
Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes
-
Kardinal C, Konkol B, Lin H, Eulitz M, Schmidt EK, Estrov Z, Talpaz M, Arlinghaus RB and Feller SM. Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. Blood. 2001; 98(6):1773-1781.
-
(2001)
Blood
, vol.98
, Issue.6
, pp. 1773-1781
-
-
Kardinal, C.1
Konkol, B.2
Lin, H.3
Eulitz, M.4
Schmidt, E.K.5
Estrov, Z.6
Talpaz, M.7
Arlinghaus, R.B.8
Feller, S.M.9
-
22
-
-
68949096693
-
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?
-
Quintas-Cardama A and Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?. Current oncology reports. 2009; 11(5):337-345.
-
(2009)
Current oncology reports
, vol.11
, Issue.5
, pp. 337-345
-
-
Quintas-Cardama, A.1
Cortes, J.2
-
23
-
-
70349306853
-
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value
-
Hochhaus A, Muller MC, Radich J, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim DW, Lipton JH, Bleickardt E, Lambert A and Hughes TP. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia. 2009; 23(9):1628-1633.
-
(2009)
Leukemia
, vol.23
, Issue.9
, pp. 1628-1633
-
-
Hochhaus, A.1
Muller, M.C.2
Radich, J.3
Branford, S.4
Kantarjian, H.M.5
Hanfstein, B.6
Rousselot, P.7
Kim, D.W.8
Lipton, J.H.9
Bleickardt, E.10
Lambert, A.11
Hughes, T.P.12
-
24
-
-
77956522589
-
Remission in CML: is DNA useful?
-
Mahon FX. Remission in CML: is DNA useful? Blood. 2010; 116(8):1192.
-
(2010)
Blood
, vol.116
, Issue.8
, pp. 1192
-
-
Mahon, F.X.1
-
25
-
-
79953295145
-
Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy
-
Kantarjian HM, Baccarani M, Jabbour E, Saglio G and Cortes JE. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(7):1674-1683.
-
(2011)
Clinical cancer research: an official journal of the American Association for Cancer Research
, vol.17
, Issue.7
, pp. 1674-1683
-
-
Kantarjian, H.M.1
Baccarani, M.2
Jabbour, E.3
Saglio, G.4
Cortes, J.E.5
-
26
-
-
8944262829
-
Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells
-
Hallek M, nhauser-Riedl S, Herbst R, Warmuth M, Winkler A, Kolb HJ, Druker B, Griffin JD, Emmerich B and Ullrich A. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. BrJ Haematol. 1996; 94(1):5-16.
-
(1996)
BrJ Haematol
, vol.94
, Issue.1
, pp. 5-16
-
-
Hallek, M.1
nhauser-Riedl, S.2
Herbst, R.3
Warmuth, M.4
Winkler, A.5
Kolb, H.J.6
Druker, B.7
Griffin, J.D.8
Emmerich, B.9
Ullrich, A.10
-
27
-
-
0017168760
-
Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia
-
Klein E, Ben-Bassat H, Neumann H, Ralph P, Zeuthen J, Polliack A and Vanky F. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. IntJ Cancer. 1976; 18(4):421-431.
-
(1976)
IntJ Cancer
, vol.18
, Issue.4
, pp. 421-431
-
-
Klein, E.1
Ben-Bassat, H.2
Neumann, H.3
Ralph, P.4
Zeuthen, J.5
Polliack, A.6
Vanky, F.7
-
28
-
-
0016640079
-
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome
-
Lozzio CB and Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975; 45(3):321-334.
-
(1975)
Blood
, vol.45
, Issue.3
, pp. 321-334
-
-
Lozzio, C.B.1
Lozzio, B.B.2
-
29
-
-
23844445433
-
Apoptin nuclear accumulation is modulated by a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells
-
Poon IK, Oro C, Dias MM, Zhang J and Jans DA. Apoptin nuclear accumulation is modulated by a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells. Cancer Res. 2005; 65(16):7059-7064.
-
(2005)
Cancer Res
, vol.65
, Issue.16
, pp. 7059-7064
-
-
Poon, I.K.1
Oro, C.2
Dias, M.M.3
Zhang, J.4
Jans, D.A.5
-
30
-
-
77949270765
-
S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3
-
Ghavami S, Eshragi M, Ande SR, Chazin WJ, Klonisch T, Halayko AJ, McNeill KD, Hashemi M, Kerkhoff C and Los M. S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3. Cell Res. 2010; 20(3):314-331.
-
(2010)
Cell Res
, vol.20
, Issue.3
, pp. 314-331
-
-
Ghavami, S.1
Eshragi, M.2
Ande, S.R.3
Chazin, W.J.4
Klonisch, T.5
Halayko, A.J.6
McNeill, K.D.7
Hashemi, M.8
Kerkhoff, C.9
Los, M.10
-
31
-
-
77950461308
-
Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c
-
Ghavami S, Mutawe MM, Hauff K, Stelmack GL, Schaafsma D, Sharma P, McNeill KD, Hynes TS, Kung SK, Unruh H, Klonisch T, Hatch GM, Los M and Halayko AJ. Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c. BiochimBiophys Acta. 2010; 1803(4):452-467.
-
(2010)
BiochimBiophys Acta
, vol.1803
, Issue.4
, pp. 452-467
-
-
Ghavami, S.1
Mutawe, M.M.2
Hauff, K.3
Stelmack, G.L.4
Schaafsma, D.5
Sharma, P.6
McNeill, K.D.7
Hynes, T.S.8
Kung, S.K.9
Unruh, H.10
Klonisch, T.11
Hatch, G.M.12
Los, M.13
Halayko, A.J.14
-
32
-
-
79551622901
-
Mevalonate cascade regulation of airway mesenchymal cell autophagy and apoptosis: a dual role for p53
-
Ghavami S, Mutawe MM, Sharma P, Yeganeh B, McNeill KD, Klonisch T, Unruh H, Kashani HH, Schaafsma D, Los M and Halayko AJ. Mevalonate cascade regulation of airway mesenchymal cell autophagy and apoptosis: a dual role for p53. PLoS One. 2011; 6(1):e16523.
-
(2011)
PLoS One
, vol.6
, Issue.1
, pp. e16523
-
-
Ghavami, S.1
Mutawe, M.M.2
Sharma, P.3
Yeganeh, B.4
McNeill, K.D.5
Klonisch, T.6
Unruh, H.7
Kashani, H.H.8
Schaafsma, D.9
Los, M.10
Halayko, A.J.11
-
33
-
-
1442327629
-
TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells
-
Guelen L, Paterson H, Gaken J, Meyers M, Farzaneh F and Tavassoli M. TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene. 2004; 23(5):1153-1165.
-
(2004)
Oncogene
, vol.23
, Issue.5
, pp. 1153-1165
-
-
Guelen, L.1
Paterson, H.2
Gaken, J.3
Meyers, M.4
Farzaneh, F.5
Tavassoli, M.6
-
34
-
-
27144508384
-
Monitoring of programmed cell death in vivo and in vitro, -new and old methods of cancer therapy assessment
-
Los M and Gibson SB, eds. (New York: Springer Academic Press)
-
Ghavami S, Barczyk K, Maddika S, Vogl T, Steinmu¨ller L, Pour-Jafari H, Evans JA and Los M. 2005. Monitoring of programmed cell death in vivo and in vitro, -new and old methods of cancer therapy assessment. In: Los M and Gibson SB, eds. Apoptotic pathways as target for novel therapies in cancer and other diseases. (New York: Springer Academic Press), pp. 323-341.
-
(2005)
Apoptotic pathways as target for novel therapies in cancer and other diseases
, pp. 323-341
-
-
Ghavami, S.1
Barczyk, K.2
Maddika, S.3
Vogl, T.4
Steinmu¨ller, L.5
Pour-Jafari, H.6
Evans, J.A.7
Los, M.8
-
35
-
-
33846396238
-
Cytotoxic effects of intra- and extracellular zinc chelation on human breast cancer cells
-
Hashemi M, Ghavami S, Eshraghi M, Booy EP and Los M. Cytotoxic effects of intra- and extracellular zinc chelation on human breast cancer cells. Eur J Pharm. 2007; 557(1):9-19.
-
(2007)
Eur J Pharm
, vol.557
, Issue.1
, pp. 9-19
-
-
Hashemi, M.1
Ghavami, S.2
Eshraghi, M.3
Booy, E.P.4
Los, M.5
|